Decreased myocardial expression of dystrophin and titin mRNA and protein in dilated cardiomyopathy: Possibly an adverse effect of TNF-α

Journal of Clinical Immunology

Volumn 30, Issue 4, 2010, Pages 520-530

  Ahmad, Shamim ^a   Rai, Taranjit Singh ^a   Khullar, Madhu ^a   Bahl, Ajay ^a   Saikia, Uma Nahar ^a   Thungapathra, M ^a   Kumar, Rohit Manoj ^a   Mahajan, Rajiv ^a   Talwar, Kewal K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Dilated cardiomyopathy; Dystrophin; Endomyocardial biopsy; Proinflammatory cytokines; Titin mRNA expression

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CONNECTIN; DYSTROPHIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; MUSCLE PROTEIN; PROTEIN KINASE; TTN PROTEIN, HUMAN;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL H9C2; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; EXON; FEMALE; GENE EXPRESSION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CASE CONTROL STUDY; CELL LINE; DOSE RESPONSE; GENETICS; HEART MUSCLE; METABOLISM;

ANIMALS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTROPHIN; HUMANS; MUSCLE PROTEINS; MYOCARDIUM; NF-KAPPA B; PROTEIN KINASES; RATS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; CONNECTIN;

EID: 77956262327     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-010-9388-3     Document Type: Article

References (30)

1. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93:841-2.
2. Towbin JA. The role of cytoskeletal proteins in cardiomyopathies. Curr Opin Cell Biol. 1998;10:131-9.
3. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM. Dilated cardiomyopathy in transgenic mice expressing a dominantnegative CREB transcription factor in the heart. J Clin Invest. 1998;101:2415-26.
4. Chien KR. Stress pathways and heart failure. Cell. 1999;98:555-8.
5. Towbin JA. Pediatric myocardial disease. Pediatr Clin North Am. 1999;46:289-312.
6. McNally E, Allikian M, Wheeler MT, Mislow JM, Hevdemann A. Cytoskeletal defects in cardiomyopathy. J Mol Cell Cardiol. 2003;3:231-41.
7. Vatta M, Stetson SJ, Jimenez S, Entman ML, Noon GP, Bowles NE, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol. 2004;43:811-7.
8. Wu Y, Cazorla O, Labeit D, Labeit S, Granzier H. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol. 2000;32:2151-62.
9. Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M, Gwathmey JK, et al. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res. 2004;95:708-16.
10. Von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin. 2009;5(4):549-60.
11. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-11.
12. Ahmad S, Otaal PS, Rai TS, Bahl A, Saikia UN, Manoj RK, et al. Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy. Mol Cell Biochem. 2009;324:139-45.
13. Paulus WJ. How are cytokines activated in heart failure? Eur J Heart Fail. 1999;1:309-12.
14. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-5.
15. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor alpha. Circ Res. 1997;81:627-35.
16. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 2000;101:2518-25.
17. Taghli-Lamallem O, Akasaka T, Hogg G, Nudel U, Yaffe D, Chamberlain JS, et al. Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype. Aging Cell. 2008;7:237-49.
18. Vatta M, Stetson SJ, Perez-Verdia A, Entman ML, Noon GP, Torre-Amione G, et al. Molecular remodeling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. Lancet. 2002;359:936-41.
19. Morano I, Hädicke K, Grom S, Koch A, Schwinger RH, Böhm M, et al. Titin, myosin light chains and C-protein in the developing and failing human heart. J Mol Cell Cardiol. 1994;26:361-8.
20. Schaper J, Froede R, Hein S, Buck A, Hashizume H, Speiser B, et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation. 1991;83:504-14.
21. Hein S, Scholz D, Fujitani N, Rennolet H, Brand T, friedl A, et al. Altered expression of titin and contractile proteins in failing human myocardium. J Mol Cell Cardiol. 1994;26:1291-306.
22. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation. 1997;95:778-81.
23. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999;83:376-82.
24. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537-44.
25. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-11.
26. Kubota T, Miyagishima M, Alvarez RJ, Kormos R, Rosenblum WD, Demetris AJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19:819-24.
27. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-9.
28. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-a in the adult mammalian heart. J Clin Invest. 1993;92:2012-303.
29. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854-65.
30. Kawamura N, Kubota T, Kawano S, Monden Y, Feldman AM, Tsutsui H, et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res. 2005;66:520-9.